A Study of Actonel for the Prevention of Bone Loss

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

LeukemiaLymphoma

Interventions

DRUG

Actonel (Risedronate)

35 mg (pill) by mouth weekly

DIETARY_SUPPLEMENT

Calcium

500 mg by mouth twice a day for a total of 24 months.

DIETARY_SUPPLEMENT

Vitamin D

400 IU by mouth twice a day for a total of 24 months.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Procter and Gamble

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00452439 - A Study of Actonel for the Prevention of Bone Loss | Biotech Hunter | Biotech Hunter